The Early Diagnosis of Hypothyroidism as a Factor in the Progression of Osteoarthritis and Comorbid Processes, the Features of Phytocorrection
Objective: to study the prevalence and forms of hypothyroidism in patients with osteoarthritis (OA) and to investigate the effect of phytomedication zobofit on the functional and morphological status of the thyroid gland, the manifestations of comorbid diseases, oxidative status, fibrinolytic and proteolytic activity of the blood. Materials and methods. In 312 patients with OA, we have studied the manifestations of comorbid processes, and among them — hypothyroidism phenomena. We have used clinical, biochemical, radioimmunological, ultrasound methods. Results. All patients with OA after 50 years had the increasing number and severity of comorbid processes. Among them, 4.48 % of patients has symptomatic and 13.78 % — subclinical hypothyroidism. Symptoms of hypothyroidism were marked in people over 55, especially — over 60 years. Subclinical hypothyroidism slightly worsened clinical symptoms of OA and comorbid processes, but enhanced the effects of oxidative stress, reduction of fibrinolytic and increase of proteolytic activity of the blood, impaired glomerular filtration rate of the kidneys. The above is considered as non-specific pathophysiological basis for the progression of identified ailments. Three-month application of the herbal medication zobofit in most patients has normalized thyroid homeostasis, improved overall outcomes of the treatment for underlying and comorbid illnesses, reduced the severity of metabolic disorders. Conclusions. In OA patients aged over 50 years with a high level of comorbidity, it is necessary to carry out screening for hypothyroidism. If you noticed the signs of subclinical hypothyroidism in this population of patients, it is appropriate to use multicomponental phytomedications with diverse thyroid-stimulating action.
Full Text:PDF (Українська)
Veremeenko NK. Proteolysis in normal and pathological conditions. К.: Zdorovia, 1993. 277 s. (Ukrainian)
Коvalenko VM. Comorbidity and ways of rational pharmacotherapy in rheumatology. Ukr. Revmatol. Zhurnal. 2014;2(56):12-13. (Ukrainian)
Fadeenko HD, Gridnev OE, Nesen AO. Comorbidity and high cardio-vascular risk is key questions of modern medicine. Ukr. Terapevt. Zhurn. 2013;1:102-107. (Ukrainian)
Кravchun NA. Clinical experience of application of the plant-based preparation Zobofit in therapy of autoimmune thyroiditis. Ukr. Med. Chasopys. 2010;4(78):47-48. (Russian)
Medical plants. Encyclopaedic reference book. Ed. NM.Grodzinskiy. К.:URЕ, 1991. 571 s.(Ukrainian)
Rheumatology. A national textbook/ Ed. VM.Kovalenko, NM. Shuba. К.: Моrion, 2013. 672 s. (Ukrainian)
Pavliuk PM. Zobofit in treatment and prevention of thyroid pathology. Fitoterapia. 2009;3:72-73. (Ukrainian)
Pankiv VI. Hypothyroidism. International Journal of Endocrinology. 2012;5(45):123-145. (Ukrainian)
Pirs S, Razvi S. Subclinical hypothyroidism: guidelines. Thyroid International. 2012;1:3-9. (Russian)
Prystupiuk OM. Hypothyroidism, system’s and organ’s disorders. Inrernational Journal of Endocrinology. 2011;4(36):104-109. (Ukrainian)
Magalias VM, Miheev AO, Rogovyi YE. Modern methodologies of experimental and clinical researches of central research laboratory of the Bukovinian State Medical Academy. Guidelines. Chernivtsi, 2001. 42 s.(Ukrainian)
Tits N. Encyclopaedia of clinical laboratory tests. М.: Labinform, 1997. 960 s. (Russian)
Fadeev VV. Modern conceptions of diagnostics and treatment of hypothyroidism in adults. Problemy Endokrinologii. 2004;2:47-53.
Fadeenko HD, Nesen AO. Comorbidity and integrative role of internal therapy. Ukr. Terapevt.Zhurn. 2015;2:7-15.
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 2008;29:76-131.
Cappola AR, Frid LP, Arnold AM. et al. Thyroid status, cardiovascular risk and mortality in older adults. JAMA. 2006;295:1033-1041.
Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Clinical and Experimental Thyroidology. 2012;8(3):11-12.
Crapo LM. Subclinical hypothyroidism and cardiovascular disease. Arch. Intern. Med. 2015;165:2451-2453.
Duntas LH, Mantzon E, Koutras DA. Effects a six month threatment with selenomethyonine in patients with autoimmune thyroiditis. Eur. J. Endocrinol. 2003;148(4):389-393.
Erdem TY, Ercan M, Ugurlu S. et al. Plasma viscosity, an early cardiovascular risk factor in women with subclinical hypothyroidism. Clin. Hoemorheol. Microcirc. 2008;38:219-225.
Francesco L, Aldo P. Autoimmune Hypothyroidism. Jn. A.P. Weetman Autoimmune Disease in Endocrinology. 2007;2:137-176.
Hak AE, Pols HA, Visser TJ. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann. Intern. Med. 2000;132(4):270-278.
Rodondy N, den Elzen WP, Bauer DC. et al. Thyroid Studies Collaboration Subclinical Hypothyroidism an the risk of coronary Heart Disease and Mortality. JAMA. 2010;304:1365-1374.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020